To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Select year:
Videos
A collection of videos showcased at our AAN 2026 Medical Affairs Booth.
Efgartigimod MoA, Indication Agnostic Video
Empasiprubart ARGX-117 Proposed Mechanism of Action video
Handouts
Downloadable resources with key insights and clinical trial updates.
VYVGART/VYVGART HYTRULO MG and CIDP Cross Indication Safety Neurology Congress Handout
Overview of neurology-specific safety data for efgartigimod (including SC formulation) from global clinical trials
VYVGART gMG ADAPT NXT Manuscript Clinical Data Summary Sheet
summary of ADAPT NXT Part A clinical data
Immunology Innovation Program Flyer
Flyer highlighting the Immunology Innovation Program and commitment to co-creating novel antibody therapies
argenx Medical Affairs: Science of Collaboration Congress Handout
Double-gate folded handout for use at medical booths and symposia (with congress-specific disclaimers), first distributed at the ANA 2025 Trainee Breakfast for neurology trainees.
Cross-indication Externally Sponsored Research Handout
A snapshot of how argenx advances immunology innovation through deep scientific collaboration and antibody engineering.
Efgartigimod Mechanism of Action Handout
ADAPT Oculus Study Design Handout
Myositis Disease State Handout
Empasiprubart 117 Proposed Mechanism of Action handout
MMN Disease State Handout
argenx Pipeline Handout for Congresses
SMA Adimanebart (ARGX-119) Trial Awareness Handout
Adapt Jr Sc HCP Card
Vyvgart Pregnancy Study gMG CIDP HCP card
VYVGART + VYVGART Hytrulo Pregnancy Registry - Referring Physician Brochure
A U.S. brochure for prescribers and gMG‑treating HCPs introducing the ARGX‑113‑PAC‑2206 pregnancy post‑approval study
ADHERE REAL Study HCP Clinical Trial Quick Card
Emnergize HCP Card
Emvigorate HCP Card
Adapt Forward HCP Card
CMS natural history HCP Card
CMS Phase 1b HCP Card
Sparkle HCP Card
Adapt Early HCP Card
Adapt Jr HCP Card
Poster/oral presentations 2026
Recent developments in the neuromuscular field.
Poster/oral presentations 2025
Recent developments in the neuromuscular field.
We couldnot find any results for your search.
Please consider trying a different term.
Items per page:
- 3
- 6
- 9
- 12
1-12 of 16
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2026 argenx MED-US-NON-2400036 v6 04/2026. All Rights Reserved.